Eve and Co - CEO, Melinda Rombouts
CEO, Melinda Rombouts
Source: The Market Herald Canada
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Eve & Co (EVE) subsidiary Natural MedCo Ltd. (NMC), delivered a C$1.8M shipment of cannabis to a German customer
  • Eve & Co received its European Union certificate of Good Manufacturing Practice (EU-GMP certification) in March of 2020
  • Eve & Co is one of a few licensed facilities in Canada able to export cannabis to the EU market
  • Eve & Co has supply agreements with ten German companies for the distribution of products throughout the EU
  • Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licences under the Cannabis Act
  • Eve & Co Incorporated (EVE) opened trading at C$0.185 per share

Eve & Co (EVE) subsidiary Natural MedCo Ltd. successfully completed its largest shipment of cannabis to date to a customer in Germany.

The shipment has a retail value of C$1.8M.

Eve & Co received its European Union certificate of Good Manufacturing Practice (EU-GMP certification) in March of 2020 and has continued to complete regular commercial shipments to its customers in Germany since the fourth quarter of 2020.

Eve & Co is one of a select few licensed facilities in Canada which is EU-GMP certified and able to export cannabis into the emerging and growing cannabis markets of the EU.

Eve & Co has supply agreements with ten German companies for the distribution of products throughout the EU.

“Our export quantities to Germany have been continually increasing as has the demand for our EU-GMP certified product by our German partners. Our EU-GMP certification provides a competitive advantage in that we are not solely reliant for revenue on the over-supplied Canadian market. We can establish our product in international markets and continually increase exports to these developing markets through our partners as their businesses grow,” said Melinda Rombouts, President and Chief Executive Officer of Eve & Co.

Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil. NMC received its cultivation licence from Health Canada in 2016.

Eve & Co Incorporated (EVE) opened trading at C$0.185 per share.

More From The Market Herald
Canopy Growth - CEO, David Klein

" Canopy Growth (TSX:WEED) reports Q4 and FY2022 financial results

Canopy Growth Corporation (WEED) has released its financial results for the fourth quarter and fiscal year ended March 31, 2022.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.